Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL13Rα2-Targeted CAR T Cells Combined With Checkpoint Inhibition for Recurrent Glioblastoma
NCT04003649Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Dec 2019
- Primary completion
- Dec 2024
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of IL13Ralpha2 hinge-optimized 41BB CAR truncated CD19-expressing autologous T-cells in glioblastoma (GBM) (3 arms), sponsored by City of Hope. Primary endpoints: Incidence of adverse events at 15 years, Dose-limiting toxicity at 28 days and 3 more. Started Dec 2019; status: active, not recruiting.
02
Drugs
IL13Ralpha2 hinge-optimized 41BB CAR truncated CD19-expressing autologous T-cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04003649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003649.